KAT14抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P02781(KAT14 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P02781(KAT14 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The KAT14 antibody is a tool used to study the KAT14 protein, a component of the histone acetyltransferase (HAT) complex. KAT14. also known as CSRP2BP or CREBBP/EP300-associated factor, belongs to the KAT2 family of acetyltransferases. It plays a role in chromatin remodeling by acetylating histones (e.g., H3 and H4), thereby regulating gene transcription. KAT14 interacts with transcriptional coactivators like CREB-binding protein (CBP) and p300. contributing to diverse cellular processes, including cell cycle regulation, DNA repair, and differentiation.

Research on KAT14 has linked it to cancer progression, neurodegenerative disorders, and developmental pathways. For example, dysregulation of KAT14-mediated acetylation may influence oncogene expression or tumor suppressor silencing. Antibodies against KAT14 are essential for detecting its expression, localization, and interactions in cells. They are widely used in techniques like chromatin immunoprecipitation (ChIP-seq), Western blotting, and immunofluorescence to explore its functional roles.

Commercial KAT14 antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes (e.g., N-terminal regions). Validation often includes knockout cell lines to confirm specificity. Researchers must verify cross-reactivity and batch consistency, as nonspecific binding can occur. Current studies focus on KAT14's involvement in disease mechanisms and its potential as a therapeutic target, driving demand for reliable antibodies in both basic and translational research.